Weixin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weixin Chen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
Bing Zhang
Beijing Center for Disease Prevention and Control Beijing China
1 shared publicationCailing Wei
Guangdong Key Lab for Diagnosis and Treatment of Emerging Infectious Diseases, Shenzhen Third People's Hospital, Southern University of Science and Technology, Shenzhen 518000, China
1 shared publication- Carl G. Feng
Immunology and Host Defence Group, The University of Sydney, Sydney, New South Wales, Australia
1 shared publication - Chi Zhang
Department of Biomedical Engineering and Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA
1 shared publication - Faiz Ur Rahman
Guangdong Provincial Key Laboratory of Postharvest Science of Fruits and Vegetables Engineering Research Center for Postharvest Technology of Horticultural Crops in South China, Ministry of Education, College of Horticulture, South China Agricultural University, Guangzhou 510642, China
1 shared publication - Haiying Liu
MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol, Guangdong Key Laboratory of Pharmaceutical Functional Genes, School of Life Sciences, Sun Yat-Sen University, Guangzhou, Guangdong, 510275, People's Republic of China.
1 shared publication
Latest Publications
- Open Access
- 6 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Retrospective cohort study of hepatitis B immunization strategy effects in Beijing across 30 years
Whether a booster dose of hepatitis B vaccine is necessary for adolescents remains controversial. We conducted a retrospective cohort study from the Immunization Information System and The National Notifiable Disease Reporting System to evaluate the impact of hepatitis B virus (HBV) vaccination programs (universal infant hepatitis B immunization and adolescent booster) on HBV infection. The vaccine effectiveness (VE) of hepatitis B vaccine is 64.43% (95% CI 57.78% − 71.08%) within 10 years of birth, escalates to 95.36% (95% CI 94.84% − 95.88%) by 20 years, and decreases to 67.35% (95% CI 63.86% − 70.85%) by 30 years. Compared with Beijing’s birth-vaccinated-only group, the booster group showed a lower relative VE in the first 10 years but a slight increase thereafter. Compared with the national control group, the booster group maintained a relatively high relative VE with a smaller decline magnitude. This study demonstrates that adolescent HBV booster vaccination administered during junior high school improves hepatitis B surface antibody levels and contributes to a further reduction in the incidence of HBV infection.
- 6 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRetrospective cohort study of hepatitis B immunization strategy effects in Beijing across 30 years
Whether a booster dose of hepatitis B vaccine is necessary for adolescents remains controversial. We conducted a retrospective cohort study from the Immunization Information System and The National Notifiable Disease Reporting System to evaluate the impact of hepatitis B virus (HBV) vaccination programs (universal infant hepatitis B immunization and adolescent booster) on HBV infection. The vaccine effectiveness (VE) of hepatitis B vaccine is 64.43% (95% CI 57.78% − 71.08%) within 10 years of birth, escalates to 95.36% (95% CI 94.84% − 95.88%) by 20 years, and decreases to 67.35% (95% CI 63.86% − 70.85%) by 30 years. Compared with Beijing’s birth-vaccinated-only group, the booster group showed a lower relative VE in the first 10 years but a slight increase thereafter. Compared with the national control group, the booster group maintained a relatively high relative VE with a smaller decline magnitude. This study demonstrates that adolescent HBV booster vaccination administered during junior high school improves hepatitis B surface antibody levels and contributes to a further reduction in the incidence of HBV infection.
- 14 December 2023
- Published by Elsevier in Scientia Horticulturae
- Vol. 326, 112772
1-methylcyclopropene combined with ethylene absorbent delays the ripening of ‘Fenjiao’ banana (Musa ABB Pisang Awak)
- 14 December 2023
- Published by Elsevier in Scientia Horticulturae
- Vol. 326, 112772
1-methylcyclopropene combined with ethylene absorbent delays the ripening of ‘Fenjiao’ banana (Musa ABB Pisang Awak)
- Open Access
- 6 July 2022
- Published by Wiley in Immunology
- Vol. 167 (2) , 221-232
The kinetics of IgG subclasses and contributions to neutralizing activity against SARS‐CoV‐2 wild‐type strain and variants in healthy adults immunized with inactivated vaccine
Neutralizing antibody is an important indicator of vaccine efficacy, of which IgG is the main component. IgG can be divided into four subclasses. Up to now, studies analysing the humoral response to SARS‐CoV‐2 vaccination have mostly focused on measuring total IgG, and the contribution of specific IgG subclasses remains elusive. The aim of this study is to investigate the kinetics of neutralizing antibodies and IgG subclasses, and to explore their relationships in people vaccinated with inactivated COVID‐19 vaccine. We conducted a prospective cohort study in 174 healthy adults aged 18–59 years old who were administrated 2 doses of CoronaVac 14 days apart and a booster dose 1 year after the primary immunization, and followed up for 15 months. Blood samples were collected at various time points after primary and booster immunization. We used live SARS‐CoV‐2 virus neutralizing assay to determine neutralizing ability against the wild‐type strain and 4 variants (Beta, Gamma, Delta and Omicron) and ELISA to quantify SARS‐CoV‐2 RBD‐specific IgG subclasses. The results showed that the 2‐dose primary immunization only achieved low neutralizing ability, while a booster shot can significantly enhance neutralizing ability against the wild‐type strain, Beta, Gamma, Delta and Omicron variants. IgG1 and IgG3 were the most abundant serum antibodies, and IgG2 and IgG4 were hardly detected at any time. The ratio of IgG1/IgG3 was positively associated with the neutralization ability. The underlying mechanism requires further exploration.
- 6 July 2022
- Published by Wiley in Immunology
- Vol. 167 (2) , 221-232
Open AccessThe kinetics of IgG subclasses and contributions to neutralizing activity against SARS‐CoV‐2 wild‐type strain and variants in healthy adults immunized with inactivated vaccine
Neutralizing antibody is an important indicator of vaccine efficacy, of which IgG is the main component. IgG can be divided into four subclasses. Up to now, studies analysing the humoral response to SARS‐CoV‐2 vaccination have mostly focused on measuring total IgG, and the contribution of specific IgG subclasses remains elusive. The aim of this study is to investigate the kinetics of neutralizing antibodies and IgG subclasses, and to explore their relationships in people vaccinated with inactivated COVID‐19 vaccine. We conducted a prospective cohort study in 174 healthy adults aged 18–59 years old who were administrated 2 doses of CoronaVac 14 days apart and a booster dose 1 year after the primary immunization, and followed up for 15 months. Blood samples were collected at various time points after primary and booster immunization. We used live SARS‐CoV‐2 virus neutralizing assay to determine neutralizing ability against the wild‐type strain and 4 variants (Beta, Gamma, Delta and Omicron) and ELISA to quantify SARS‐CoV‐2 RBD‐specific IgG subclasses. The results showed that the 2‐dose primary immunization only achieved low neutralizing ability, while a booster shot can significantly enhance neutralizing ability against the wild‐type strain, Beta, Gamma, Delta and Omicron variants. IgG1 and IgG3 were the most abundant serum antibodies, and IgG2 and IgG4 were hardly detected at any time. The ratio of IgG1/IgG3 was positively associated with the neutralization ability. The underlying mechanism requires further exploration.
- Open Access
- 25 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103905
Corrigendum to ‘single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis’ [EBioMedicine 53 (2020) 102686]
- 25 February 2022
- Published by Elsevier in EBioMedicine
- Vol. 77, 103905
Open AccessCorrigendum to ‘single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis’ [EBioMedicine 53 (2020) 102686]